M344: Potent HDAC Inhibitor (IC50 100 nM) for Cancer and HIV-1 Latency Research

Executive Summary: M344 is a highly potent, cell-permeable histone deacetylase (HDAC) inhibitor with an IC50 of 100 nM, produced by APExBIO (M344); it induces histone acetylation and gene expression changes in multiple cancer cell lines (e.g., MCF-7, D341 MED, CH-LA 90) and enhances HIV-1 LTR activation in latency models. The compound demonstrates effective growth inhibition (GI50 ≈ 0.63–0.65 μM) and acts as a radiation sensitizer in human squamous carcinoma cells. M344 is insoluble in water but dissolves in DMSO (≥14.75 mg/mL) and ethanol (≥12.88 mg/mL) with warming and sonication. At concentrations above 10 μM, toxicity increases and only a fraction of cells differentiate, highlighting the importance of dose optimization (source). Recent studies confirm less favorable toxicity in Wistar rat brain slices compared to SAHA, underscoring the need for careful application in neurobiology (related article).

Biological Rationale

Histone deacetylases (HDACs) regulate chromatin structure and gene expression by removing acetyl groups from lysine residues on histones. Inhibition of HDACs increases histone acetylation, leading to relaxed chromatin and activation of transcription. This mechanism can induce differentiation, apoptosis, or growth arrest in cancer cells. M344 specifically targets HDAC enzymes, making it an essential research tool for studies in epigenetic regulation, cancer biology, and viral latency. The compound’s potency, cell permeability, and solubility profile enable its application in diverse in vitro and ex vivo models (APExBIO).

Mechanism of Action of M344

M344 inhibits HDAC enzymatic activity with an IC50 of 100 nM, resulting in increased global and locus-specific histone acetylation. This chromatin remodeling upregulates or reactivates gene expression, including tumor suppressor genes and latent viral promoters. In cancer models, this leads to cell cycle arrest, apoptosis, and increased differentiation. In HIV-1 latency studies, M344 activates the HIV-1 LTR, partly via modulation of the NF-κB pathway. The compound’s cell permeability allows efficient nuclear access, essential for epigenetic modulation at physiological concentrations (1–100 μM). M344’s mechanism is validated by acetylation assays and expression profiling in multiple cell lines (contrasts by focusing on mechanistic depth in tumor microenvironment studies).

Evidence & Benchmarks

• M344 exhibits an HDAC inhibition IC50 of 100 nM in cell-based assays (APExBIO).
• Growth inhibition (GI50) values for MCF-7 (breast cancer), D341 MED (medulloblastoma), and CH-LA 90 (neuroblastoma) cells are 0.63–0.65 μM under standard culture conditions (37°C, 5% CO₂, 72 h) (internal review).
• M344 increases histone H3 acetylation levels as measured by Western blot and ELISA after 24–48 h exposure at 1–10 μM (mechanistic update).
• In HIV-1 latency models, M344 activates LTR-driven gene expression via NF-κB modulation at 1–5 μM, as shown by luciferase reporter assays (Smith 2023, DOI).
• In human squamous carcinoma cell lines (SCC-35, SQ-20B), M344 enhances the cytotoxic response to radiation, supporting its use as a radiation sensitizer (strategic application review).
• In Wistar rat brain slice cultures, M344 demonstrates higher toxicity compared to SAHA at equivalent concentrations (>10 μM, 24 h) (APExBIO).

Applications, Limits & Misconceptions

M344 is a versatile research compound for:

• Cell-based cancer proliferation, apoptosis, and differentiation assays (especially in breast cancer, neuroblastoma, and medulloblastoma cells).
• Epigenetic studies involving histone acetylation and chromatin accessibility.
• HIV-1 latency reversal and LTR activation research.
• Radiation sensitization in squamous carcinoma cell lines.
• Comparative studies of HDAC inhibitor toxicity and efficacy.

However, its toxicity profile (notably in neural tissues) and solubility restrictions (insoluble in water) impose boundaries on its use. For a practical guide, see this article (which focuses on cell-based assay workflows, whereas the present article emphasizes mechanistic and translational context).

Common Pitfalls or Misconceptions

• M344 is not suitable for in vivo administration due to poor water solubility and limited pharmacokinetic data.
• Long-term storage of M344 solutions (even in DMSO or ethanol) is discouraged, as degradation can affect activity.
• High concentrations (>10 μM) may induce toxicity unrelated to HDAC inhibition, confounding experimental interpretation.
• M344 does not replace pan-HDAC inhibitors in all contexts; its profile differs from agents like SAHA or trichostatin A.
• Not all cancer cell lines respond equally; resistance mechanisms may affect outcomes in certain models.

Workflow Integration & Parameters

M344 (SKU A4105) is supplied as a solid by APExBIO and should be stored at -20°C. For experimental use, dissolve in DMSO (≥14.75 mg/mL) or ethanol (≥12.88 mg/mL) with warming (37°C) and sonication. Use freshly prepared solutions and avoid prolonged storage. Recommended working concentrations are 1–100 μM, with treatment durations from 1 to 7 days depending on cell type and assay endpoint. Toxicity is observed above 10 μM in sensitive lines. Optimal readouts include cell proliferation (GI50), histone acetylation (ELISA, Western blot), apoptosis (Annexin V/PI), and gene expression assays (qPCR, luciferase). For workflow details and troubleshooting, see this protocol-focused article (which complements the present mechanistic overview).

Conclusion & Outlook

M344 is a robust, cell-permeable HDAC inhibitor with nanomolar potency and broad applicability in cancer and HIV-1 latency research. Its defined mechanism, experimental benchmarks, and workflow integration make it a preferred tool for studies of epigenetic modulation and gene regulation. As research advances, further comparative studies—especially in neural models and combination therapies—will clarify M344’s translational potential relative to other HDAC inhibitors. For ongoing developments in tumor microenvironment applications, see this article (which this article updates by emphasizing dose-response and toxicity boundaries).